Jarushka: Ross

Ross is ferocious on this point. In interviews and grand rounds, she repeatedly notes that up to 20% of lung cancer deaths occur in never-smokers. She points out the rise of EGFR and ALK mutations in young, non-smoking women—a cohort that is mysteriously increasing.

While pharmaceutical reps were handing out brochures about the "power of immunotherapy," Ross was publishing landmark papers in The New England Journal of Medicine and The Lancet Oncology detailing the "when" and "how" of these toxicities. She created the first algorithms for community oncologists to manage a patient who develops sudden diabetes or a heart arrhythmia from a checkpoint inhibitor. “We can’t just turn off the immune system without turning off the fight against the cancer,” she has argued. “It’s a balance. We need to be smarter than the biology.” One of the most striking things about Ross is her refusal to let patients carry the burden of guilt. Lung cancer carries a unique shame that breast or colon cancer does not: the assumption that the patient "did it to themselves" via smoking. jarushka ross

While other researchers were celebrating the remission rates, Ross noticed the collateral damage. Patients whose lungs were clearing up were suddenly in emergency rooms with inflamed colons, arthritic joints, or, most frighteningly, swollen brains. This is Ross’s signature contribution to the field. She became the world’s leading expert on immune-related adverse events (irAEs) . Ross is ferocious on this point

Landing at the , Ross found herself at ground zero of the immunotherapy revolution. This wasn’t just chemotherapy anymore; this was teaching the body’s own immune system to see a tumor as an invader. But there was a dark side to this miracle. While pharmaceutical reps were handing out brochures about